Open in interactive viewer → charts, metric popovers & call review

InspireMD's TCAR Approval Comes With a Term Sheet

CGuard Prime finally gets its U.S. label, but a concurrent equity raise and a still-recalled CAS system make the relaunch a financing story as much as a commercial one.
NSPR · Earnings Call · 2026-11-12

Approval arrives, but so does the term sheet

On November 12, InspireMD finally converted its long-running TCAR regulatory story into a label. The FDA approved the CGuard Prime TransCarotid Stent System for TCAR procedures, a milestone CEO Marvin Slosman called one of the most significant in company history.

With FDA approval of our CGuard Prime TransCarotid Stent System for TCAR procedures, we are returning to the U.S. market with our next-generation carotid implant, supported by a strong body of clinical evidence, which we believe positions us to significantly expand our market penetration...

Marvin Slosman, CEO · 2026-11-12
The claim is not empty: management says the indication adds roughly 40,000 annual U.S. procedures and effectively doubles the addressable opportunity, backed by 75,000 global procedures and CGUARDIANS II data showing 100% acute device success in 50 patients. That is real clinical evidence. It is not yet commercial revenue. The third quarter shows the gap. Revenue was $2.2 million, down 11% year over year; international sales were $2.2 million, up 9%; U.S. sales were about $32,000, primarily from the CGUARDIANS III trial. The U.S. business was effectively off-line after the May voluntary recall of the CGuard Prime 135 delivery system. So the approval is the starting gun for commercial execution, not proof of it. Slosman insists the company is ready: “We are ready, and product is being shipped as we speak... we are not only ready to go, but past ready to go, and products are moving today.” — Marvin Slosman, CEO · 2026-11-12 Investors will want to see that in Q4 revenue rather than in adjectives.